Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Price Target at $50.00

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average rating of “Hold” from the six brokerages that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $50.00.

Several equities analysts have recently commented on the company. Wells Fargo & Company reduced their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Barclays increased their price target on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Bank of America cut their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Finally, Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th.

Omnicell Stock Up 1.7 %

Omnicell stock opened at $44.35 on Thursday. The business has a 50-day simple moving average of $44.60 and a 200 day simple moving average of $42.37. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of -113.72, a PEG ratio of 29.73 and a beta of 0.78.

Insider Activity

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares of the company’s stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.64% of the company’s stock.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently added to or reduced their stakes in OMCL. GAMMA Investing LLC lifted its stake in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the last quarter. KBC Group NV lifted its position in Omnicell by 60.8% in the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the last quarter. 1620 Investment Advisors Inc. boosted its stake in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after buying an additional 1,542 shares during the period. Summit Global Investments bought a new position in Omnicell during the third quarter valued at $221,000. Finally, QRG Capital Management Inc. purchased a new stake in shares of Omnicell in the third quarter valued at $231,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.